Related Experiment Video

Updated: May 24, 2026

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination
09:38

Determining Immune System Suppression versus CNS Protection for Pharmacological Interventions in Autoimmune Demyelination

Published on: September 12, 2016

Interferon-beta in pediatric multiple sclerosis patients: safety in short-term prescription

Keivan Basiri1, Masood Etemadifar, Fatemeh Derakhshan

  • 1Neuroscience Research Center, Isfahan University of Medical Sciences, Iran.

Acta Medica Iranica
|February 24, 2012
PubMed

Insights

Interferon-beta treatments, including Avonex and Betaferon, show promise for pediatric multiple sclerosis (MS) patients. This study found these therapies effective and safe in children with relapsing-remitting MS (RRMS).

Area of Science:

  • Neurology
  • Immunology
  • Pediatric Medicine

Background:

  • Multiple Sclerosis (MS) treatments approved for adults are not officially approved for pediatric patients.
  • Pediatric MS patients currently receive off-label immunomodulatory drug therapies.
  • There is a need for effective and safe treatments for children with MS.

Purpose of the Study:

  • To evaluate the effectiveness and tolerability of interferon beta1-a (Avonex) and interferon beta1-b (Betaferon) in pediatric patients with relapsing-remitting MS (RRMS).
  • To assess the safety and short-term complications of these treatments in children.

Main Methods:

  • A study involving thirteen pediatric patients (under 16) diagnosed with definite RRMS.
  • Six patients received intramuscular interferon beta1-a (Avonex) weekly; seven received subcutaneous interferon beta1-b (Betaferon) every other day.
  • Patients were treated with standard adult doses, gradually increased from half dose.

Main Results:

  • After nine months, 69.2% of patients experienced no relapses, and the remaining four had only one relapse.
  • The mean Expanded Disability Status Scale (EDSS) score significantly decreased post-treatment.
  • No short-term complications or safety concerns were reported.

Conclusions:

  • Interferon-beta therapy demonstrates reasonable effectiveness and safety in pediatric MS patients.
  • Further research with larger sample sizes and longer follow-up is needed to confirm long-term impacts.
  • These findings support the consideration of interferon-beta for treating pediatric MS.

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions01:24

Drug Accumulation During Multiple Dosing: Intermittent IV Infusions

Intermittent intravenous (IV) infusion is a method of drug administration where medications are delivered over short infusion periods followed by intervals of no drug delivery. This approach helps to prevent sustained high drug concentrations in the bloodstream, reducing the risk of adverse effects associated with prolonged exposure. Unlike continuous infusion, steady-state concentrations may not be achieved during a single dosing cycle but can be reached through repeated...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...